Yuhan

Showing 1 posts of 1 posts found.

janssen_latest_logo_on_sign_closer

J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn

November 6, 2018
Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …

The Gateway to Local Adoption Series

Latest content